Clinical trials: Alopecia Areata
Alopecia Areata
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks.
- Trial name
- NCT02974868
- Testing
- PF-06651600, PF-06700841
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 142 people
- Sponsor
- Pfizer
Chemotherapy Adjuvant, Breast Cancer
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
The efficacy and safety of the Dignicap System to prevent chemotherapy induced alopecia will be evaluated in women with early breast cancer undergoing adjuvant or neoadjuvant chemotherapy regimens.
- Trial name
- NCT01831024
- Testing
- Dignicap System
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Target Health Inc.
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Hair Care, Hair Loss
Olistic_2025 for Hair Loss, Hair Growth, and Skin Improvement
The goal of this randomized, double-blind, placebo-controlled clinical trial is to find out whether daily oral intake of the nutraceutical Olistic Next Women can reduce hair loss, improve hair growth and quality, and improve…
- Conditions
- Hair Care, Hair Loss, Female Pattern Hair Loss
- Trial name
- NCT07300813
- Testing
- Olistic Next Women
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionos Biotech S.L.
Androgenetic Alopecia
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males
The overall purpose of this clinical investigation is to collect data to support a marketing application for over the counter use of the X5 HairLaser with an indication for hair growth.
- Trial name
- NCT02067260
- Testing
- X5 HairLaser
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Spencer Forrest, Inc.
Androgenetic Alopecia (AGA)
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06622824
- Testing
- KX-826 0.5% BID, KX-826 1.0% BID
- Where
- China
- Volunteers
- 756 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)
Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451112
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP2 (NCT05914805)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 762 people
- Sponsor
- Cassiopea SpA
Alopecia Areata
Excimer Light(308) Therapy for Resistant Alopecia Areata
This study aimed to evaluate the efficacy and safety of the 308-nm excimer lamp in resistant AA treated with topical minoxidil .
- Trial name
- NCT06149936
- Testing
- excimer light
- Volunteers
- 20 people
- Sponsor
- Assiut University
Covid19, Telogen Effluvium
COVID-19 Induced Telogen Effluvium
This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection
- Conditions
- Covid19, Telogen Effluvium, SARS-CoV Infection, Alopecia
- Trial name
- NCT04834102
- Testing
- Blood Tests
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istanbul Medeniyet University
Androgenetic Alopecia
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following…
- Trial name
- NCT04984707
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Cicatricial Alopecia
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known…
- Trial name
- NCT05076006
- Testing
- PF-06700841
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Emma Guttman
Alopecia
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
The purpose of this study is to evaluate hairstyling techniques aimed at increasing efficacy of scalp cooling in the prevention of chemotherapy-induced alopecia, determine scalp cooling effect on persistent chemotherapy-induced…
- Trial name
- NCT05213936
- Testing
- Scalp cooling with hairstyle, Scalp cooling with conditioner and water emulsion
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Montefiore Medical Center
Alopecia Areata
Evaluation of the Efficacy of Systemic Treatments for Alopecia (ESTAA)
The aim of our study was to retrospectively assess the efficacy and safety of systemic treatments in patients with alopecia areata, by recruiting cases from the HUGO network (Hôpitaux Universitaires du Grand Ouest), a network of…
- Trial name
- ESTAA (NCT06471114)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Brest
Hair Thinning, Hair Loss
Impact of a Topical Cosmetic Product on Women's Hair
The proposed pilot study will investigate the impact of a daily topical nutritional product applied to women's hair, specific to perceived hair quality and overall well-being.
- Trial name
- NCT06060834
- Testing
- Topical Botanical Agent
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Memphis
Alopecia Areata
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
- Trial name
- Allegro2a (NCT04517864)
- Testing
- PF-06651600
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Alopecia
Evaluating Vibrational Anesthesia in Scalp Platelet Rich Plasma (PRP)
This study is prospective, single-site, randomized split-scalp pilot and survey study of patients at the NYU Skin and Cancer Clinic or the Faculty Group Practice.
- Trial name
- NCT06497764
- Testing
- Vibrational Anesthesia (VA) Device, PRP Treatment
- Where
- United States
- Sponsor
- NYU Langone Health
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451099
- Testing
- Autologous cultured dermal cells
- Where
- 6 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia
Fractional Non-ablative Laser for the Treatment of Hair Loss
This is a single center, prospective, open label clinical trial with before-after study design. The study is designed to evaluate the feasibility of hair growth in female and male pattern hair loss (androgenic alopecia, telogen…
- Trial name
- NCT04953416
- Testing
- 1565nm non ablative fractional laser
- Where
- Ukraine
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.